{
  "id": 492478,
  "title": "Nirsevimab's RSV Protection Didn't Extend to Second Year",
  "url": "https://urgent.news/2026/08/10/nirsevimabs-rsv-protection-didnt-extend-to-second-year",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T17:23:09.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/pediatrics/rsv/122550"
  },
  "original_language": "en",
  "account": "Monoclonal antibody nirsevimab (Beyfortus) demonstrated notable efficacy in preventing respiratory syncytial virus (RSV)-related lower respiratory tract infection (LRTI) hospitalizations in infants during their first year following administration, according to a nationwide cohort study from France. The research, published in JAMA Pediatrics, revealed a 66% effectiveness estimate in a 2023 birth cohort and a 72% estimate in a 2024 birth cohort, both representing significant risk reductions. However, the protective effects of nirsevimab did not persist into the second year for RSV-LRTI hospitalizations, as indicated by a weighted hazard ratio (wHR) of 1.03 with a 95% confidence interval (95% CI) of 0.73-1.43 in the 2023 cohort. Despite maintaining effectiveness against RSV-LRTI during the first year, the study found no association between nirsevimab receipt at baseline and subsequent RSV-related LRTI hospitalizations in the second year, with a wHR of 1.03. Furthermore, the vaccine did not show any link to reduced hospitalizations due to non-RSV infections or asthma in infants during their first year after receiving the treatment. Although nirsevimab was associated with higher rates of hospitalization for ENT bacterial infections and asthma during the second year, these connections should be considered alongside the substantial reduction in RSV-LRTI-related hospitalizations and warrant further investigation in ongoing studies.",
  "summary": "(MedPage Today) -- The monoclonal antibody nirsevimab (Beyfortus) consistently performed well against respiratory syncytial virus (RSV)-related hospitalization during infants' first year after receipt but without a benefit for other hospitalizations...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}